SEC Form 4 · accession 0001213900-18-002426
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Amzak Capital Management, LLC
10% Owner
Gerald J Kazma
10% Owner
Michael D Kazma
10% Owner
Period of report
Feb 26, 2018
Accepted (ET)
Feb 28, 2018 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value of $0.0001F1 | Feb 26, 2018 | S | 1,500 | $11.00 | D | 256,091 | D | |
| Common Stock, par value of $0.0001F2,F1 | Feb 27, 2018 | S | 80,880 | $8.357 | D | 175,211 | D | |
| Common Stock, par value of $0.0001F3 | Feb 27, 2018 | S | 5,901 | $8.263 | D | 0 | I | Owned by Michael D. Kazma, manager of Amzak Capital Management, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed on this Form 4, each of whom is a manager of the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.61, inclusive. The Reporting Persons undertake to provide to Zosano Pharma Corp. ("Zosano"), any security holder of Zosano, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in footnotes (2) and (3) of this Form 4.
- F3These shares were sold in multiple transactions at prices ranging from $8.20 to $8.35, inclusive.